Atopic Dermatitis

Atopic Dermatitis

CONDITION

Skin

GENDER

Both males and females

AGE GROUP

18 years and above

TRIAL STATUS

Completed

This research project is testing the safety, tolerability and efficacy (the effect of the drug on the body) of AKP-11 administered to participants with atopic dermatitis. You are invited to take part in the study, which will enrol participants with atopic dermatitis based on diagnosis by a suitably qualified “Investigator” or “study doctor”.

If you are eligible, you will receive daily ointment of the study medication, from Day 1 through up to Day 28. After screening, you wil attend the clinic a total of 6 times. The AKP-11 will be applied twice-daily for up to 28 days.

If you are interested and would like more information, please contact:

Stephanie Buchanan – Study Coordinator

Phone: 9623 9448

Email sbuchanan@skincancer.asn.au

Website: https://www.ctc.asn.au/trials/AD

Eligible participants in this clinical study will receive reimbursement for their time and travel. Bellberry Ethics Committee has approved this study.

CONTACT DETAILS

Phone Number: +61 3 9623 9448
Email: sbuchanan@skincancer.asn.au
Location: Carlton, Victoria, Australia

CONTACT SITE

Approved By: Bellberry Ethics Committee              

Clinical Trial Registry Link: